Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist ...

A 66-year-old man whose kidneys were failing is now the fourth person who has received a gene-edited pig kidney, ...

Indian drugmaker Maithili Life Sciences has received a non-compliant report from the Brussels-based Federal Agency for ...

The life science investment firm Bioluminescence Ventures will close its doors less than two years after its founding, ...

Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech found success with a different B cell-killing ...

Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...

Acelyrin merges with Alumis in all-stock deal, transferring $448M cash and lonigutamab asset. Martin Babler to lead combined ...

Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans for regulatory filing this year.

Cystic fibrosis biotech Sionna Therapeutics will raise $191 million in its upsized Nasdaq debut on Friday, and metabolic disease biotech Aardvark Therapeutics outlined plans for a potential $89 ...

After promoting its oncology officer Chris Boshoff to chief scientific officer last fall, Pfizer has found his successor.

AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for ...

AstraZeneca on Thursday provided insight on an ongoing China probe into the company concerning alleged illegal drug imports, ...